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ABSTRACT 
Objective 
Data on the association between subclinical thyroid dysfunction and dementia are 
limited and conflicting. We aimed to determine whether subclinical thyroid 
dysfunction was associated with dementia and cognitive decline.  
Design 
Population-based prospective cohort study.  
Patients 
Adults aged 70-79 years with measured thyroid function, but no dementia at baseline, 
and Modified Mini-Mental State (3MS) at baseline and follow-up.  
Measurements 
Primary outcome was incident adjudicated dementia, based on 3MS, hospital records, 
and dementia drugs. Secondary outcome was change in 3MS. Models were adjusted 
for age, sex, race, education, and baseline 3MS, and then further for cardiovascular 
risk factors.  
Results 
Among 2558 adults, 85% were euthyroid (TSH 0.45-4.49mIU/L), 2% had subclinical 
hyperthyroidism with mildly decreased TSH (TSH 0.10- 0.44mIU/L), 1% subclinical 
hyperthyroidism with suppressed TSH (TSH<0.10mIU/L with normal free thyroxine 
[FT4]) and 12% subclinical hypothyroidism (TSH 4.50-19.99mIU/L with normal 
FT4). Over 9 years, 22% developed dementia. Compared to euthyroidism, risk of 
dementia was higher in participants with subclinical hyperthyroidisim with suppressed 
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TSH (HR 2.38, 95%CI=1.13;5.04), while we found no significant association in those 
with mildly decreased TSH (HR 0.79, 95%CI=0.45;1.38) or with subclinical 
hypothyroidism (HR 0.91, 95%CI=0.70;1.19). Participants with subclinical 
hyperthyroidism with suppressed TSH had a larger decline in 3MS (-3.89, 95%CI=-
7.62;-0.15). Conclusions  
Among older adults, subclinical hyperthyroidism with a TSH<0.10mIU/L was 
associated with a higher risk of dementia and a larger cognitive decline, while 
subclinical hyperthyroidism with mildly decreased TSH or subclinical hypothyroidism 
were not.  
 
INTRODUCTION 
Subclinical thyroid dysfunction (SCTD), defined as abnormal TSH with normal free 
thyroxine (FT4), is strongly associated with age, with a prevalence of 4.5% for 
subclinical hyperthyroidism (SHyper) and 20% for subclinical hypothyroidism 
(SHypo) in the over-60 population.
1-3
 Similarly, dementia is common with aging, 
reaching a prevalence of 7-10% after 60 years.
4
 
Cognitive impairment is associated with overt thyroid dysfunction,
5,6
 but data on 
SCTD are limited and conflicting. SHyper was associated with cognitive impairment 
or dementia in one retrospective
7
 and two cross-sectional studies.
8,9
 Our recent meta-
analysis of prospective cohorts found SHyper, but not SHypo, was associated with 
dementia, while decline in Mini-Mental State Examination (MMSE) was similar in 
both conditions, when compared with euthyroidism.
10
 However, most studies 
presented limitations: short time of follow-up, no dementia adjudication, incomplete 
assessment of potential confounding variables.
10
 Additionally, study-level meta-
analyses of observational studies are subject to potential bias (ecological fallacy), and 
do not allow reliable subgroup analyses, e.g. stratified by sex.
11
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If SCTD is associated with a higher risk of dementia, the mechanisms may be complex 
and at least partially depend on the relationship of SCTD with cardiovascular risk 
factors.
12
 SCTD is indeed associated with coronary heart disease and arterial stiffness, 
with the latter a probable risk factor for vascular dementia.
12,13
 
We examined in a large prospective cohort study of older adults with a long follow-up 
time and high-quality data, the association of SCTD with dementia and cognitive 
decline, and the potential role of cardiovascular risk factors in this relationship.  
 
MATERIAL AND METHODS 
Reporting is in accordance with the STrengthening the Reporting of OBservational 
studies in Epidemiology (STROBE) statement.
14
 
Study population 
Participants were part of the Health, Aging and Body Composition (Health ABC) 
study, a prospective cohort study of 3075 community-dwelling adults, aged 70-79 
years at enrollment (1997–1998) and followed over ten years. Participants were 
recruited from a random sample of white Medicare beneficiaries and all black people 
living in designated zip code areas in and around Memphis (Tennessee) or Pittsburgh 
(Pennsylvania). Race was assessed because of potential differences in health 
outcomes. The study excluded participants with dementia, who had difficulty with 
activities of daily living, could not walk a quarter of a mile, could not climb 10 steps 
without resting, had life-threatening cancer, or planned to move out of the area in the 
next three years. The Health ABC Study was approved by the institutional review 
boards of the clinical sites (University of Tennessee, Memphis, and University of 
Pittsburgh) and the coordinating center (University of California, San Francisco). All 
participants gave written informed consent. For this analysis, we included participants 
with cognition assessed by Modified Mini-Mental State (3MS) at Year 1 visit 
(baseline visit of Health ABC) and at least at one follow-up visit, and with measured 
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TSH but no dementia at Year 2, leading to a sample of 2601 participants out of 3075 
Health ABC participants. We excluded 25 of them for primary hypothyroidism, one 
for overt secondary hypothyroidism, six for overt primary hyperthyroidism, two for 
receiving anti-thyroid drugs at Year 2, eight for receiving amiodarone at Year 2, and 
one for dementia at Year 2, leaving 2558 participants in the analysis. Because of 3MS 
examination at Year 1 and TSH measurement at Year 2, we did a sensitivity analysis 
excluding participants with a difference in 3MS of >5 points between Year 1 and Year 
3.  
Measurements 
Thyroid function  
TSH and FT4 were measured at Year 2 visit in a central laboratory at the University of 
Vermont, by immunoassay for TSH and by competitive immunoassay for FT4 (ACS; 
Chiron Diagnostics Corp, Emeryville, Calif). The coefficient of variation for TSH was 
4.71% at 0.30mIU/L, and 3.64% at 15.85mIU/L, according to the manufacturer. 
Normal range for FT4 with this assay is 10.3-23.2pmol/L (0.8-1.8ng/dL). In the Health 
ABC Study, FT4 was measured only if TSH was <0.1 or >7.0mIU/L.
15
 Categories of 
thyroid function were defined as: euthyroidism (TSH=0.45-4.49mIU/L), SHyper 
(TSH<0.45mIU/L with FT4 within the normal range when TSH<0.1mIU/L), SHypo 
(TSH=4.50-19.99mIU/L with FT4 within the normal range when TSH>7.0mIU/L), 
primary overt hyperthyroidism (TSH<0.45mIU/L with FT4>23.2pmol/L), secondary 
overt hyperthyroidism (TSH≥4.50mIU/L with FT4>23.2pmol/L), primary overt 
hypothyroidism (TSH≥4.50mIU/L with FT4<10.3pmol/L, or TSH>19.99mIU/L), and 
secondary overt hypothyroidism (TSH<0.45mIU/L with FT4<10.3pmol/L). SHyper 
was further categorized as mildly decreased TSH (TSH 0.10-0.44mIU/L) or 
suppressed TSH (TSH<0.10mIU/L). 
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Cognitive assessment  
Our primary outcome was incident adjudicated dementia. Change in 3MS over time 
was our secondary outcome.  
Dementia was adjudicated by an expert committee composed of a same panel of 
experienced medical doctors during the whole follow-up period. This committee 
identified dementia diagnosis on medical records using a predefined adjudication 
form. Dementia was defined by any of the following criteria: 1) ≥1.5 standard 
deviation (SD) race-stratified 3MS decline from Year 1 visit to last available 
examination; 2) dementia as primary or secondary diagnosis of admission on hospital 
records with 3MS ≤90 points at Year 3 or either follow-up (participants were asked 
about hospital admissions twice a year); 3) prescription of dementia drug (donepezil, 
galantamine, memantine, rivastigmine, or tacrine) recorded on the yearly drug 
inventory. Date of first available record of dementia diagnosis was used to define 
onset.  
The 3MS (score of 0-100 point(s), the higher the better), provides a more complete 
and more sensitive assessment of global cognitive function than the traditional 
MMSE.
16
 It evaluates attention, basic language, conceptualization, construction, 
memory, orientation praxis, and verbal fluency. In the Health ABC study, it was 
conducted at Years 1, 3, 5, 8, 10, and 11. Because of high number of missing 3MS at 
Year 11, we stopped the analysis at Year 10. A few participants had missing 3MS at 
Year 10, but had 3MS available at Year 11 (N=55); in these cases, we used Year 11 
3MS for Year 10. 
Definition of baseline characteristics and other potential confounders 
Baseline demographic and social characteristics included age, sex, race (white or 
black), and education (less than high school, high school graduate and some college, 
college graduate). Literacy was included at Year 3, based on the Rapid Estimate of 
Adult Literacy in Medicine (REALM).
17
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Baseline health characteristics included body mass index (BMI; measured as weight in 
kilograms divided by height in squared meters), smoking history (current, past, or 
never smokers), drinking history (<1, 1-7 or >7 drinks/week within the last 12 
months), weekly exercise (<500, 500<1500, or ≥1500kcal/week), and medication. 
Hypertension was defined by self-report of a diagnosis (“told by a doctor”), use of an 
antihypertensive drug, or elevated blood pressure measurement (systolic blood 
pressure ≥140mmHg or diastolic blood pressure ≥90mmHg). Diabetes was defined by 
self-report of a diagnosis (“told by a doctor”), use of an antidiabetic drug, fasting 
plasma glucose ≥126mg/dL (7.0mmol/L), or 2-hour 75g glucose tolerance test 
>200mg/dL (11.1mmol/L), according to the American Diabetes Association criteria in 
place in 2002, i.e. near the baseline visits of Health ABC.
18
 Depression was defined as 
≥16 points on the 20-item Center for Epidemiologic Studies-Depression Scale.19 
Biological parameters included fasting total cholesterol, high-density lipoprotein 
cholesterol, low-density lipoprotein cholesterol, triglycerides, glucose, and creatinine, 
measured by a calorimetric technique (Johnson & Johnson Vitros 950 analyzer, New 
Brunswick, New Jersey).   
Statistical analysis 
For this analysis, baseline was defined as first TSH measurement, i.e. Year 2 visit, as 
previously done in Health ABC.
15
 Participants who died before developing dementia 
were censored from the analysis at death date.
20,21
 Time-to-dementia was defined as 
the interval between baseline evaluation of thyroid function and first diagnosis of 
dementia or censoring from observation at the last available dementia evaluation. For 
all the analyses, we compared participants with SHyper with mildly decreased or 
suppressed TSH, and those with SHypo to euthyroids (reference).  
We used a multivariable Cox regression model to assess the association between 
thyroid dysfunction and cause-specific incident dementia, taking into account baseline 
3MS.
20-22
 We presented results as hazards ratio (HR) with 95% confidence interval 
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(CI). To generate cumulative incidence graphs, we used a competing-risks regression 
model, based on Fine and Gray’s method, and took into account incidence of death.20-
22
  
To select the confounding factors, we first chose variables that may be confounding 
factors, based on previous publications and biological plausibility. The potential 
confounding factors included age, sex, race, education level, REALM, depression, and 
study site. We then used a forward stepwise selection using the P-values of 
statistically significant associations in univariable analysis (P<0.05). We adjusted for 
variables that were statistically significantly associated with both dementia and SCTD. 
Among them, age, sex, race, and education level were significantly associated with 
both dementia and SCTD. We therefore adjusted the main analysis for those potential 
confounding factors. In a second model, we further adjusted for cardiovascular risk 
factors since they could additionally confound an association between SCTD and 
dementia. We tested the association of smoking status, alcohol consumption, physical 
activity, BMI, diabetes mellitus, blood pressure, lipid values, C-reactive protein, 
fasting glucose, and glycated hemoglobin with both dementia and SCTD. We 
extended our final statistical models with those cardiovascular risk factors 
significantly associated with both dementia and SCTD: HDL-cholesterol, C-reactive 
protein, alcohol consumption, and diastolic blood pressure. 
In a secondary analysis, we analyzed 3MS change from baseline to last follow-up. 
Because of 3MS non-normal distribution, we first calculated the change from baseline 
in 3MS for each participant, which had a near normal distribution, and then used it to 
investigate the association between thyroid function and 3MS. We used a repeated 
measures linear mixed-effects model, with a random intercept for each patient to 
account for the repeated measurement in different follow-up assessments, and 
accounting for missing values at follow-up to assess difference in 3MS change 
according to thyroid function, while controlling for age, sex, race, and education. 
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Results were presented as difference in adjusted mean change of 3MS between 
euthyroid participants and those with SHyper with mildly decreased or suppressed 
TSH, or SHypo.  
We performed several sensitivity analyses: (i) Excluding participants with thyroxine 
medication at baseline to assess the risk of endogenous SCTD. (ii) Including only 
participants with thyroxine medication at baseline to assess the effect of exogenous 
thyroxine over substitution. (iii) Excluding participants with 3MS drop >5 points 
between Years 1 and 3, as baseline was defined as Year 2.  
To improve statistical efficiency, we finally assessed the relationship of thyroid 
function with dementia and cognitive decline using fractional polynomials to capture 
the non-linear association between TSH as a continuous variable and dementia or 
cognitive decline, adjusting for the same potential confounding factors as in the main 
analysis. Finally, we tested these associations using log-transformed TSH as a 
continuous variable. 
For all analyses, we assessed effect modification by sex, race, education, and 
depression. If there was consistent evidence for effect modification (P<0.05), we 
presented the results stratified by the levels of the effect modifier. We found no 
significant interaction, except by sex but only in the association between dementia and 
SHyper with mildly decreased TSH (P=0.04), and not between dementia and SHyper 
with suppressed TSH, SHypo or TSH as a continuous variable (P=0.46, P=0.34 and 
P=0.14, respectively). Because of lack of consistent interaction by sex, we didn’t 
provide stratified analyses by sex. All tests were two-sided, at a 0.05 level of 
significance. All analyses were done with STATA release 13.1 (StataCorp LP, College 
Station, Texas). 
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RESULTS 
Baseline characteristics 
Mean (SD) age of the participants was 75.1 (2.8) years, with 51.8% women. Mean 
(SD) TSH was 2.64 (2.13) mIU/L. At baseline, 22 (0.9%) participants had SHyper 
with suppressed TSH, 58 (2.3%) had SHyper with mildly decreased TSH, 315 (12.3%) 
had SHypo, and 253 (9.9%) were on thyroxine medication. Table 1 presents baseline 
characteristics of participants according to thyroid function. Participants with SHyper 
with mildly decreased TSH were older and more likely to be women.  
Subclinical thyroid dysfunction and risk of dementia 
During 22457 person-years of follow-up (median 9 years), 574 (22.4%) participants 
developed dementia; 493 (85.9%) were euthyroid, 7 (1.2%) had SHyper with 
suppressed TSH, 13 (2.3%) had SHyper with mildly decreased TSH, and 61 (10.6%) 
had SHypo. Figure 1 shows the cumulative incidence of dementia according to thyroid 
function. The risk of dementia was higher in  SHyper with suppressed TSH (adjusted 
HR=2.38, 95%CI=1.13;5.04), but not in SHyper with mildly decreased TSH (adjusted 
HR=0.79, 95%CI=0.45;1.38, Table 2). SHypo was not associated with dementia 
(adjusted HR=0.91, 95%CI=0.70;1.19, Table 2). We found no significant association 
of TSH with dementia in the continuous analysis using fractional polynomials 
(P=0.10, Appendix Figure 1) or using log-transformed TSH (P=0.19, Appendix Figure 
2). 
Results of the Cox regression were unchanged after further adjusting for 
cardiovascular risk factors (Table 2). Results were similar in the sensitivity analysis 
excluding participants with thyroxine medication at baseline (Table 2). 
In the sensitivity analysis restricted to participants with thyroxine medication at 
baseline (N=253), the adjusted HR for dementia in SHyper with suppressed TSH was 
1.66, 95%CI=0.50;5.53, and HR=1.98, 95%CI=0.58;6.75 after further adjustment for 
cardiovascular risk factors. The sensitivity analysis that excluded 645 participants with 
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3MS drop >5 points between Years 1 and 3 yielded similar results, with an adjusted 
HR for dementia of 2.71 (95%CI 1.20; 6.10) for SHyper with suppressed TSH. 
Subclinical thyroid dysfunction and change in 3MS  
During the 10-year follow-up period, participants with SHyper with suppressed TSH 
had a larger decline in 3MS (adjusted 3MS mean change -3.89, 95%CI=-7.62;-0.15) 
than euthyroid participants (Table 3 and Figure 2). Conversely, we found no 
significant difference in adjusted mean 3MS change for participants with SHyper with 
mildly decreased TSH, or SHypo (Table 3 and Figure 2). After further adjustment for 
cardiovascular risk factors, our results remained unchanged (Table 3). In the 
sensitivity analysis that excluded participants on thyroxine medication at baseline, 
point estimates were similar, but no longer statistically significant (Table 3). In the 
sensitivity analysis that excluded 645 participants with 3MS drop >5 points between 
Years 1 and 3, adjusted 3MS mean change was -3.07 (95%CI=-6.40;0.25) for SHyper 
with suppressed TSH. Adjusted 3MS mean change was not associated with TSH as a 
continuous variable either in the fractional polynomials analysis (P=0.17, Appendix 
Figure 3) or as a log-transformed variable (P=0.21, Appendix Figure 4). 
 
DISCUSSION 
In this prospective cohort of older community-dwelling adults, we found SHyper with 
suppressed TSH was associated with a higher risk of dementia and a larger decrease in 
cognition, while SHyper with mildly decreased TSH or SHypo were not. All results 
were similar after adjusting for cardiovascular risk factors.  
Previous retrospective or cross-sectional studies showed an association of SHyper with 
dementia or cognitive impairment.
7-9
 Although the association between SHyper and 
dementia was not significant in individual prospective studies, a recent meta-analysis 
of those studies found a HR for dementia of 1.67 (95%CI=1.04;2.69) in SHyper.
10
 
Interestingly, we found that only SHyper with suppressed TSH was associated with 
dementia, while SHyper with mildly decreased TSH was not. These results suggest 
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that there may be a threshold above which higher thyroid function increases the risk of 
dementia. However, we cannot exclude power insufficiency as an explanation for the 
lack of association between SHyper with mildly decreased TSH and dementia, because 
of the relatively small number of participants with SHyper.   
Compared to euthyroids, participants with  SHyper with suppressed TSH had a larger 
decrease in 3MS. Previous prospective data are scarce. The MRC Cognitive Function 
and Ageing Study found a larger MMSE decrease with high normal FT4.
23
 
Conversely, in the recent meta-analysis of prospective studies, both SHyper and 
SHypo were not associated with faster decline in MMSE.
10
 The differences in results 
might be explained by a relative short follow-up time in previous studies (33 months), 
and the modest sensitivity of MMSE compared to 3MS.
16
 Furthermore, it may be due 
to the degree of SHyper, which was not assessed in previous studies, as in our study 
3MS decline was not larger in participants with SHyper mildly decreased TSH. We 
found no previous study using 3MS. 
Several pathophysiological pathways could explain the relationship between 
hyperthyroid dysfunction and dementia. First, dementia may be caused by an increase 
in neuronal necrosis
24
 and oxidative stress associated with both hyperthyroidism
25
 and 
Alzheimer disease.
26
 Second, a genetic susceptibility may exist, as some thyroid 
hormones target genes are involved in neurogenesis.
27
 Third, dementia could be 
caused by lower choline in the brain, as described in Alzheimer disease.
28
 In a pilot 
study, choline/creatine ratio in the brain was indeed lower in patients with untreated 
Graves’ disease, but normalized after treatment.29 We hypothesize that the relationship 
between SHyper and cognitive function may run along similar paths.   
Two previous studies assessed the association between TSH as a continuous variable 
and the risk of dementia: the Rotterdam Study
30
 found a significantly lower risk of 
dementia with higher TSH levels in both the full range and the reference range (HR 
0.90, 95%CI=0.83;0.98 and HR 0.76, 95%CI=0.64;0.91, respectively). Similarly, the 
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Cardiovascular Heart Study
31
 found a lower risk of dementia with higher TSH levels 
within the reference range (HR 0.87, 95%CI 0.76;1.00, P=0.05). Both studies found a 
similar higher risk of dementia with higher FT4 levels (HR 1.04, 95%CI=1.01;1.07 
and 1.04, 95%CI=0.97;1.10 per pmol/L increase in FT4 in the Rotterdam Study and in 
the Cardiovascular Heart Study, respectively), although the association was not 
significant in the Cardiovascular Heart Study, except when comparing only quartiles 1 
and 4 (difference of -9.6 per 1000 person years, 95%CI=-17.9;-1.2), or when 
excluding participants with positive antithyroid peroxidase antibodies (HR 0.84, 
95%CI=0.72;0.98, P=0.02). Although we found no significant association between 
TSH and dementia in our continuous analyses, the trend for a higher risk of dementia 
with lower TSH levels and the significantly increased risk of dementia in participants 
with SHyper with suppressed TSH are consistent with those previous studies.  
We found no significant association of SHypo with either dementia or cognitive 
decline. This is consistent with the results of two previous meta-analyses
10,32
 and of 
the recent TRUST trial that found no benefit of thyroxine replacement on executive 
cognitive function as measured by the letter-digit coding test.
33
 Conversely, another 
meta-analysis found a significant association in participants younger than 75 years 
only.
34
 These conflicting findings may be related to the older age of our participants. 
However, the results of this latter meta-analysis should be interpreted in light of some 
limitations, as it included heterogeneous study designs (both retrospective and 
prospective studies) and didn’t assess dementia as an endpoint, and as the TRUST trial 
did not find different results according to age.
33
 
Our study had some limitations. First, since thyroid function was only measured once 
as in most prospective cohorts, we may have misclassified participants with transient 
TSH abnormality, or included participants who developed overt dysfunction over time. 
Second, because FT4 was only measured if TSH was <0.1 or >7.0mIU/L, we may 
have included participants with overt instead of subclinical thyroid dysfunction, 
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although overt thyroid dysfunction is uncommon with TSH 0.1-7.0mIU/L.
35
 Third, 
thyroid function was assessed at Year 2, i.e. one year after baseline evaluation of 
Health ABC; however, we excluded participants with new dementia at Year 2, and 
conducted a sensitivity analysis excluding participants with 3MS drop >5 points 
between Years 1 and 3, which yielded similar results. Fourth, we did not assess 
different types of dementia, or measure thyroid auto-antibodies. Fifth and finally, our 
results suggested that the association between SCTD and cognitive impairment was 
not confounded by cardiovascular risk factors only, but a confounding effect could 
have been masked by dementia types other than vascular.  
Our study presents several strengths and novelties in comparison with previous 
analyses. First, we included an unselected community-dwelling population without 
dementia at baseline. Second, the prospective design of the study allows a risk 
assessment and avoids potential bias related to retrospective analyses. Third, the 
follow-up time was longer than in most previous studies (median 9 years versus 44.4 
months in the recent meta-analysis of prospective cohort studies).
10
 Fourth, we 
assessed a large number of potential confounding factors, including cardiovascular 
risk factors, and performed stratified analyses to identify potentially relevant 
interactions. Fifth, we studied both dementia and cognitive decline; while some 
subjectivity may remain when diagnosing dementia, the 3MS is an objective, sensitive 
and validated test to identify cognitive impairment. Sixth, we assessed thyroid 
function not only using TSH as a continuous variable, but also according to categories 
of SCTD, which may be clinically more relevant. Finally, unlike in most previous 
studies, diagnosis of dementia was adjudicated by an expert committee, reducing the 
risk of misclassification, and was based on several criteria including not only clinical 
diagnosis, but also the objective 3MS, as well as the prescription of dementia drugs. In 
conclusion, in this prospective cohort study, we found that SHyper with suppressed 
TSH was associated with a higher risk of dementia and a larger decrease in cognitive 
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performance. SHyper with mildly decreased TSH and SHypo were not associated with 
dementia or decreased cognitive performance. Further prospective studies with a larger 
sample size or an individual participant data analysis with information on different 
types of dementia and with a larger number of participants with SHyper are warranted 
to confirm our results and ascertain more specific associations.  
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Table 1. Baseline characteristics of the whole cohort, and according to thyroid function 
Characteristics 
Total 
(N=2558) 
Euthyroidis
m (N=2163) 
SHypo 
(N=315) 
P-value 
a 
SHyper with 
TSH 0.10-
0.44mIU/L 
(N=58) 
P-value 
b 
SHyper with 
TSH 
<0.10mIU/L 
(N=22) 
P-value 
c 
Socio-demographics         
    Age, years  75.1 (2.8) 75.1 (2.9) 75.3 (2.7) 0.34 75.9 (3.0) 0.04 75.8 (3.2) 0.28 
    Women 1326 (51.8) 1095 (50.7) 175 (55.6) 0.10 42 (72.4) 0.001 14 (63.6) 0.23 
    Race, White 1567 (61.3) 1284 (59.4) 236 (74.9) <0.0001 34 (58.6) 0.91 13 (59.1) 0.98 
    Site, Memphis 1286 (50.3) 1082 (50.0) 160 (50.8) 0.80 31 (53.5) 0.61 13 (59.1) 0.40 
    Education level    0.003 c  0.48 c  0.57 c 
        < High school graduate 
        High school graduate 
        College graduate         
592 (23.2) 
833 (32.7) 
1126 (44.1) 
523 (24.3) 
694 (32.2) 
939 (43.6) 
49 (15.6) 
111 (35.2) 
155 (49.2) 
 
13 (22.4) 
23 (39.7) 
22 (37.9) 
 
7 (31.8) 
5 (22.7) 
10 (45.5) 
 
    REALM ≥60 (Y3) 506 (20.9) 433 (21.2) 54 (17.8)  12 (21.8) 0.92 7 (33.3) 0.18 
Smoking status    0.20 c
 
 0.34 c  0.08 c 
    Never 
    Former 
    Current 
1143 (44.7) 
1179 (46.1) 
233 (9.1) 
956 (44.3) 
1000 (46.3) 
204 (9.4) 
144 (45.7) 
151 (47.9) 
20 (6.4) 
 
28 (48.3) 
8 (13.8) 
22 (37.9) 
 
15 (68.2) 
1 (4.6) 
6 (27.3) 
 
Alcohol, drinks/week    0.83 c  0.11 c  0.10 c 
    <1 
    1-7 
    >7 
1796 (70.4) 
567 (22.2) 
187 (7.2) 
1513 (70.1) 
483 (22.4) 
161 (7.5) 
215 (68.7) 
75 (24.0) 
23 (7.4) 
 
48 (82.8) 
8 (13.8) 
2 (3.5) 
 
20 (90.9) 
1 (4.6) 
1 (4.6) 
 
3MS at Year 1 
e 
90.6 (7.9) 90.4 (8.1) 91.7 (7.1) 0.01 92.0 (6.8) 0.15 91.0 (8.4) 0.72 
Depression at Year 1
f 
113 (4.5) 96 (4.5) 13 (4.1) 0.99 1 (1.7) 0.42 1 (4.6) 0.84 
Physical activity, kcal/week    0.02 c  0.40 c   
    <500 
    500-<1500 
1293 (50.6) 
714 (27.9) 
1112 (51.4) 
595 (27.5) 
137 (43.5) 
95 (30.2) 
 
33 (856.9) 
17 (29.3) 
 
11 (50.0) 
7 (31.8) 
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    ≥1500 551 (21.5) 456 (21.1) 83 (26.4) 8 (13.8) 4 (18.2) 
Hypertension 
 
1822 (71.2) 1566 (72.4) 199 (63.7) 0.001 41 (70.7) 0.77 16 (72.7) 0.97 
Diabetes mellitus 
 
468 (18.3) 400 (18.5) 48 (15.2) 0.16 14 (24.1) 0.28 6 (27.3) 0.29 
Body mass index, kg/m
2 27.4 (4.8) 27.5 (4.9) 26.8 (4.5) 0.02 26.6 (3.9) 0.16 26.6 (4.1) 0.39 
Systolic blood pressure 135.2 (20.7) 135.7 (20.7) 133.0 (20.6) 0.04 132.3 (24.2) 0.23 133.0 (20.6) 0.54 
Diastolic blood pressure 71.1 (11.6) 71.4 (11.8) 69.7 (10.3) 0.01 67.8 (12.1) 0.02 71.7 (12.4) 0.92 
Lipoproteins         
    Total cholesterol, mmol/l 
    HDL-cholesterol, mmol/l 
    LDL-cholesterol, mmol/l 
    Triglycerides, mmol/l 
5.3 (1.0) 
1.4 (0.4) 
3.1 (0.9) 
1.6 (0.9) 
5.3 (1.0) 
1.4 (0.4) 
3.1 (0.9) 
1.6 (0.9) 
5.5 (1.0) 
1.43 (0.4) 
3.2 (0.9) 
1.7 (1.0) 
0.01 
0.03 
0.25 
0.01 
5.1 (0.9) 
1.5 (0.5) 
3.1 (0.8) 
1.5 (0.8) 
0.22 
0.30 
0.60 
0.74 
4.6 (0.7) 
1.3 (0.3) 
2.8 (0.7) 
1.6 (1.5) 
0.003 
0.33 
0.06 
0.66 
 
Abbreviations: FT4, free thyroxine; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 3MS, Modified Mini-Mental State; N, number; REALM, Rapid 
Estimate of Adult Literacy in Medicine; SD, standard deviation; SHyper, subclinical hyperthyroidism; SHypo, subclinical hypothyroidism. 
There were seven participants with missing data for education level, 139 for REALM, three for smoking status, eight for alcohol consumption, 19 for depression, 
119 for total cholesterol, 113 for LDL-cholesterol, and 82 for HDL-cholesterol. Values are mean (SD) or n (%). For some covariates, there were missing values that 
were excluded. 
a
 P-value for the difference between euthyroidism and SHypo. 
b
 P-value for the difference between euthyroidism and SHyper with mildly decreased TSH (0.10-0.44mIU/L). 
c
 P-value for the difference between euthyroidism and SHyper with suppressed TSH (<0.10mIU/L). 
d
 P-value over groups. 
e
 The 3MS ranges from 0 to a best score of 100 points.  
f Depression was defined as a score ≥16 on the 20-item Center for Epidemiologic Studies-Depression Scale (CES-D). 
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Table 2. Adjusted hazard ratios for the risk of dementia in subclinical hyperthyroidism with suppressed 
TSH, subclinical hyperthyroidism with mildly decreased TSH and subclinical hypothyroidism, compared 
with euthyroidism. 
 N dementia/ N total in 
participants with 
subclinical thyroid 
dysfunction 
N dementia/ 
N total in 
euthyroid 
participants 
HR (95%CI)
 
Subclinical hyperthyroidism    
Main analysis 
a
  
   Suppressed TSH 
b
  
   Mildly decreased TSH 
c 
 
7/22 
13/58 
230/1066 
261/1090 
2.38 (1.13;5.04) 
0.79 (0.45;1.38) 
Adjusting for cardiovascular risk factors 
d,e 
   Suppressed TSH 
b
  
   Mildly decreased TSH 
c
 
 
7/22 
13/55 
224/1026 
248/1049 
 
2.41 (1.14;5.10) 
0.80 (0.46;1.39) 
Excluding participants with thyroxine 
medication at baseline
f
  
   Suppressed TSH 
b
  
   Mildly decreased TSH 
c
 
 
5/14 
5/28 
 
218/1024 
228/960 
 
3.03 (1.13;8.15) 
0.82 (0.37;1.85) 
 
   
Subclinical hypothyroidism    
Main analysis 
a
 61/315 491/2156 0.91 (0.70;1.19) 
Adjusting for cardiovascular risk factors 
d,e
 59/309 472/2075 0.89 (0.68;1.17) 
Excluding participants with thyroxine 
medication at baseline 
f
 
53/267 456/1984 0.96 (0.72;1.27) 
 
Abbreviations: CI, confidence interval; 3MS, Modified Mini-Mental State; N, number; HR, hazard ratio. 
a
 The main analysis was adjusted for age, sex, race, education level and 3MS at baseline. There were 7 missing values for 
education level, all in participants with euthyroidism (2 participants with dementia, 5 participants without dementia). 
b 
Suppressed TSH was defined as TSH <0.10mIU/L. 
c 
Mildly decreased TSH was defined as TSH 0.10-0.44mIU/L.
 
d
 Further adjustment for cardiovascular risk factors that were associated with subclinical thyroid dysfunction and dementia: high 
density lipoprotein cholesterol (HDL-cholesterol), C-reactive protein, alcohol consumption and diastolic blood pressure.  
e
 Number of missing values for cardiovascular risk factors in the study population: n=82 for HDL-cholesterol, 21 for C-reactive 
protein, n=8 for alcohol consumption, n=0 for diastolic blood pressure. 
f
 253/2558 (9.9%) participants had thyroxine medication at baseline. 
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Table 3. Difference in adjusted mean change from baseline over all time 
points for 3MS, in subclinical hyperthyroidism with suppressed TSH, 
subclinical hyperthyroidism with mildly decreased TSH and subclinical 
hypothyroidism, compared with euthyroidism. 
 Difference in adjusted mean change 
(95% CI) 
Main analysis 
a
 
Subclinical hyperthyroidism 
   Suppressed TSH
 b 
   Mildly decreased TSH 
c 
Subclinical hypothyroidism   
 
-3.89 (-7.62;-0.15) 
-0.24 (-2.34;1.85) 
-0.01 (-0.98;0.95) 
Adjusting for cardiovascular risk factors 
d,e
 
Subclinical hyperthyroidism 
   Suppressed TSH
 b
 
   Mildly decreased TSH 
c
 
Subclinical hypothyroidism   
 
-3.86 (-7.60;-0.13) 
-0.27 (-2.40;1.86) 
0.18 (-0.80;1.15)
 
Excluding participants with thyroxine medication at baseline 
f
 
Subclinical hyperthyroidism 
   Suppressed TSH
 b
 
   Mildly decreased TSH 
c
 
Subclinical hypothyroidism   
 
-3.33 (-8.36;1.70) 
-1.30 (-4.27;1.68) 
-0.14 (-1.18;0.90)
 
 
Abbreviations: CI, confidence interval; HR, hazard ratio; 3MS, Modified Mini-Mental 
State; N, number; TSH, thyroid-stimulating hormone. 
a
 The main analysis was adjusted for age, sex, race, and education level. There were 7 
missing values for education level, all in participants with euthyroidism (2 participants with 
dementia, 5 participants without dementia).
 
b 
Suppressed TSH was defined as TSH <0.10mIU/L. 
c 
Mildly decreased TSH was defined as TSH 0.10-0.44mIU/L.
 
d
 Further adjustment for cardiovascular risk factors that were associated with subclinical 
thyroid dysfunction and dementia: high density lipoprotein cholesterol (HDL-cholesterol), 
C-reactive protein, alcohol consumption and diastolic blood pressure.  
e
 Number of missing values for cardiovascular risk factors in the study population: n=82 for 
HDL-cholesterol, 21 for C-reactive protein, n=8 for alcohol consumption, n=0 for diastolic 
blood pressure. 
f
 253/2558 (9.9%) participants had thyroxine medication at baseline. 
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FIGURES CAPTIONS 
Figure 1.  
Title: Cumulative adjusted incidence of dementia in subclinical thyroid dysfunction 
compared with euthyroidism. 
Legend: A) subclinical hyperthyroidism with suppressed TSH (TSH <0.10mIU/L) or 
with mildly decreased (TSH 0.10-0.44mIU/L) B) subclinical hypothyroidism. Analyses 
were adjusted for age, sex, race, education level and baseline 3MS.  
Figure 2.  
Title: 3MS change from baseline in subclinical thyroid dysfunction compared with 
euthyroidism. 
Legend: A) subclinical hyperthyroidism with suppressed TSH (TSH <0.10mIU/L) or 
with mildly decreased (TSH 0.10-0.44mIU/L) B) subclinical hypothyroidism. Analyses 
were adjusted for age, sex, race and education level. Abbreviations: CI, confidence 
interval; 3MS, Modified Mini-Mental State; SHyper, subclinical hyperthyroidism; 
SHypo, subclinical hypothyroidism.  
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